Citadel Advisors’s Bone Biologics BBLG Stock Holding History

Citadel Advisors’s Portfolio BBLG Stock Details BBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.7K	Buy	+23,879	New	+$31.2K	﹤0.01%	13283
2026 Q1	–	Sell	-10,844	Closed	-$15.7K	–	12978
2025 Q4	$15.7K	Buy	+10,844	New	+$21.6K	﹤0.01%	12393
2023 Q4	–	Sell	-236	Closed	-$8.05K	–	14260
2023 Q3	$8.05K	Buy	+236	New	+$11.7K	﹤0.01%	13223
2022 Q2	–	Sell	-7	Closed	-$30K	–	12864
2022 Q1	$30K	Buy	+7	New	+$25.4K	﹤0.01%	13099

Other funds holding BBLG

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citadel Advisors's BBLG Position: Q2 2026 in Review

Citadel Advisors opened a new position in Bone Biologics (BBLG) in Q2 2026: 23,879 shares worth $32.7K. The stake represents ﹤0.01% of the portfolio and ranks #13283 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BBLG as recently as Q4 2025.

Citadel Advisors first reported a position in BBLG in Q1 2022 and has held it in 4 quarters since. 3 funds tracked by Wall St. Rank hold BBLG as of Q2 2026.

Citadel Advisors held 23,879 shares of Bone Biologics worth $32.7K as of Q2 2026.
Bone Biologics was a new Citadel Advisors position in Q2 2026.
Bone Biologics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13283 holding.
Citadel Advisors first reported a position in Bone Biologics in Q1 2022 and has held it in 4 quarters since.
3 funds tracked by Wall St. Rank held Bone Biologics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.